XILIO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 USD | +7.92% |
|
-5.22% | +98.18% |
| 04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| 04-01 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Chart calendar Xilio Therapeutics, Inc.
91e8b1e16fb2dcf42bc.kuswfsBvYPFkp8Uk-IM3VeNYGoIEAqAZCVzLbUfGlU4.zbxeDqMDFdwN4oRHksdlLbYITdE0ce54QSb-Xgux2C32jlIPmR5QxwbSjA~a9af5390f4de8f8de7e09c370f6629f4
Upcoming events on Xilio Therapeutics, Inc.
Past events on Xilio Therapeutics, Inc.
| 28/03/2024 12:00 | Business Update Call |
| 04/03/2024 15:30 | TD Cowen Health Care Conference |
| 27/02/2024 | Q4 2023 Earnings Release (Projected) |
| 07/02/2024 17:30 | Guggenheim Healthcare Talks Biotechnology Conference |
| 09/11/2023 21:01 | Q3 2023 Earnings Release |
| 06/11/2023 | European Society for Medical Oncology Immuno-Oncology Congress |
| 06/11/2023 13:00 | Business Update Call |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract No:1056 |
| 03/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract No:611 |
| 11/09/2023 19:55 | Morgan Stanley Global Healthcare Conference |
| 14/08/2023 12:30 | Q2 2023 Earnings Release |
| 08/06/2023 21:00 | Annual General Meeting |
| 09/05/2023 12:30 | Q1 2023 Earnings Release |
| 16/04/2023 18:30 | American Association for Cancer Research Meeting - Abstract No: 587 |
| 16/04/2023 18:30 | American Association for Cancer Research Meeting - Abstract No: 572 |
| 13/03/2023 20:00 | Oppenheimer Healthcare Conference |
| 06/03/2023 14:10 | Cowen Health Care Conference |
| 02/03/2023 21:06 | Q4 2022 Earnings Release |
| 23/02/2023 14:00 | Citi Virtual Oncology Leadership Summit |
| 09/02/2023 20:55 | Guggenheim Oncology Conference |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 7,50 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -73,5 -77,9 5.53% | -87,3 -87,9 0.65% | 0,00 -76,5 - | -55,3 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -75,0 -80,1 6.31% | -89,1 -87,5 -1.86% | -79,1 -78,9 -0.33% | -69,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -75,8 -78,3 3.23% | -88,2 -84,6 -4.25% | -76,4 -76,6 0.21% | -67,4 |
|
Net income Million USD | Released Forecast Spread | -55,2 | -75,8 -78,3 3.23% | -88,2 -84,6 -4.25% | -76,4 -76,6 0.21% | -67,4 |
|
EPS USD | Released Forecast Spread | -11,1 | -13,5 -6,28 -115.29% | -3,22 -3,09 -4.38% | -2,78 -2,79 0.24% | -1,64 |
| Announcement Date | 24/05/21 | 01/03/22 | 02/03/23 | 01/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 10,0 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -19,2 -24,0 20.16% | -20,8 -23,1 9.91% | -24,1 -21,6 -11.61% | -19,7 -25,0 21.07% | -22,7 -21,0 -7.99% | -23,0 -28,3 18.49% | -19,6 -24,0 18.23% | -16,9 -20,0 15.5% | -16,8 | 12,3 | -18,3 | -17,0 | -17,0 | -18,5 |
|
EBIT Million USD | Released Forecast Spread | -19,6 -25,3 22.79% | -21,2 -25,0 15.12% | -24,6 -21,5 -14.43% | -20,2 -24,0 15.93% | -23,2 -20,5 -13.01% | -23,5 -24,8 5.12% | -20,1 -24,1 16.51% | -17,4 -22,4 22.63% | -18,1 -18,4 1.49% | -2,70 | -19,5 | -19,8 | -21,3 | -19,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -19,7 -22,2 11.36% | -21,4 -24,9 14.21% | -24,6 -21,5 -14.66% | -19,8 -24,0 17.61% | -22,5 -20,5 -9.86% | -22,6 -24,6 7.93% | -19,4 -23,8 18.68% | -16,7 -22,2 24.51% | -17,7 -17,8 1.07% | -0,41 | -19,4 | -19,8 | -21,3 | -19,0 |
|
Net income Million USD | Released Forecast Spread | -19,7 -22,2 11.36% | -21,4 -24,9 14.21% | -24,6 -21,5 -14.65% | -19,8 -24,0 17.61% | -22,5 -20,5 -9.86% | -22,6 -24,6 7.93% | -19,4 -23,8 18.67% | -16,7 -22,2 24.51% | -17,7 -17,8 1.08% | -0,40 | -19,4 | -19,8 | -21,3 | -18,9 |
|
EPS USD | Released Forecast Spread | -0,98 -0,92 -6.52% | -0,78 -1,00 21.61% | -0,90 -0,78 -15.38% | -0,72 -0,88 17.87% | -0,82 -0,74 -10.31% | -0,83 -0,89 6.21% | -0,70 -0,87 19.31% | -0,61 -0,80 24.07% | -0,64 -0,65 1.03% | -0,08 | -0,46 | -0,48 | -0,52 | -0,14 |
| Announcement Date | 01/03/22 | 12/05/22 | 09/08/22 | 09/11/22 | 02/03/23 | 09/05/23 | 14/08/23 | 09/11/23 | 01/04/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Xilio Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- XLO Stock
- Calendar Xilio Therapeutics, Inc.
